Fig. 4 - Supplemetal 7

DH5 maintained robust kinase inhibitory activity. (A, B) SRC kinase activity was measured in vitro to assess inhibitory activities of dasatinib (A) and DH5 (B). A purified, catalytically active SRC(251-536), at a concentration of 0.8 μM, was incubated with a serial dilution of either dasatinib or DH5. The IC50 for each compound was determined from their dose-response curves. n = 3. Data are shown as mean ± s.e.m.

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Elife